title: Leukocyte reduction of blood components: public policy and new technology.
authors.affiliation: Blood Transfusion Service, Massachusetts General Hospital, Boston 02114, USA.
authors.forename: S
authors.initials: S
authors.lastname: Dzik
authors.forename: J
authors.initials: J
authors.lastname: Aubuchon
authors.forename: L
authors.initials: L
authors.lastname: Jeffries
authors.forename: S
authors.initials: S
authors.lastname: Kleinman
authors.forename: C
authors.initials: C
authors.lastname: Manno
authors.forename: M F
authors.initials: MF
authors.lastname: Murphy
authors.forename: M A
authors.initials: MA
authors.lastname: Popovsky
authors.forename: M
authors.initials: M
authors.lastname: Sayers
authors.forename: L E
authors.initials: LE
authors.lastname: Silberstein
authors.forename: S J
authors.initials: SJ
authors.lastname: Slichter
authors.forename: E C
authors.initials: EC
authors.lastname: Vamvakas
mesh_terms: D000276:Adjuvants, Immunologic; D001781:Blood Component Removal / Q000009:adverse effects / Q000191:economics / Q000592:standards*; D016913:Blood Component Transfusion / Q000009:adverse effects / Q000191:economics / Q000592:standards*; D003365:Costs and Cost Analysis; D007562:Creutzfeldt-Jakob Syndrome / Q000517:prevention & control; D005060:Europe; D006801:Humans; D007107:Immune System / Q000503:physiopathology; D007962:Leukocytes / Q000276:immunology*; D011640:Public Policy; D014481:United States
chemical_list: D000276:Adjuvants, Immunologic